| Patent application number | Description | Published |
|---|
| 20090304683 | Soluble Fragments of The Sars-Cov Spike Glycoprotein - The invention relates to the spike protein from the virus (SARS-CoV) that is etiologically linked to severe acute respiratory syndrome (SARS); polypeptides and peptide fragments of the spike protein; nucleic acid segments and constructs that encode the spike protein, polypeptides and peptide fragments of the spike protein, and coupled proteins that include the spike protein or a portion thereof; peptidomimetics; vaccines; methods for vaccination and treatment of severe acute respiratory syndrome; antibodies; aptamers; and kits containing immunological compositions, or antibodies (or aptamers) that bind to the spike protein. | 12-10-2009 |
| 20100055033 | ANTIBODY COMPOSITIONS AND METHODS FOR TREATMENT OF NEOPLASTIC DISEASE - Antibody compositions and methods for treatment of neoplastic disease in a mammalian subject are provided. Methods of diagnosing cancer in a mammalian subject are also provided. | 03-04-2010 |
| 20100316641 | ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES - Described herein are engineered antibody constant domain molecules, such as CH2 or CH3 domain molecules, comprising at least one mutation, or comprising at least one complementarity determining region (CDR), or a functional fragment thereof, engrafted in a loop region of the CH2 domain. The CH2 domain molecules described herein are small, stable, soluble, exhibit little to no toxicity and are capable of binding antigen. | 12-16-2010 |
| 20100317837 | IDENTIFICATION OF NOVEL BROADLY CROSS-REACTIVE NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES USING SEQUENTIAL ANTIGEN PANNING OF PHAGE DISPLAY LIBRARIES - The present invention provides a method of identifying novel broadly crossreactive neutralizing monoclonal antibodies using sequential antigen panning of phage display libraries, antibodies obtained in accordance with such a method, as well as fusion proteins and conjugates comprising same, and related isolated or purified nucleic acid molecules, vectors, host cells, compositions, and methods of use to inhibit an infection, reduce the severity of an infection, treat an infection, and inhibit cancer. | 12-16-2010 |
| 20110008358 | HUMAN MONOCLONAL ANTIBODIES THAT SPECIFICALLY BIND IGF-II - Disclosed herein are isolated monoclonal human antibodies that specifically binds insulin-like growth factor II (IGF-II) with an equilibrium dissociation constant (K | 01-13-2011 |
| 20110020344 | HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR CD22 - Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (K | 01-27-2011 |
| 20110020361 | HUMAN ANTI-MESOTHELIN MONOCLONAL ANTIBODIES - Disclosed herein are isolated human monoclonal antibodies that specifically bind human mesothelin with a binding affinity of about 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human mesothelin in a sample. Methods of diagnosing cancer, or confirming a diagnosis of cancer, are disclosed herein that utilize these antibodies. Methods of treating a subject with cancer are also disclosed. | 01-27-2011 |
| 20110104163 | ANTI-HIV DOMAIN ANTIBODIES AND METHOD OF MAKING AND USING SAME - The invention provides single domain antibodies and derivatives thereof that bind antigens of interest, which are stable, soluble, and do not tend to aggregate. The invention also provides methods for constructing a dAb library and methods for screening dAb libraries to identify the dAb of the invention. The invention also provide methods of treating or preventing conditions by antigen neutralization by administering the dAbs of the invention. | 05-05-2011 |
